The Effect of Laughter Therapy in Women

Status Completed

Clinical Trial Summary

Migraine: An episodic disorder consisting of severe headache, usually with photophobia (sensitivity to light), phonophobia (sensitivity to sound), and/or nausea (occasionally vomiting). Migraine is predominantly a female disease. The incidence of migraine was found to in women (18.2/1000 person-years) and between the ages of 15-19 in men (6.2/1000 person-years). The incidence of migraine was found to peak between the ages of 20-24 in women (18.2/1000 person-years) and between the ages of 15-19 in men (6.2/1000 person-years). Migraine treatments are generally classified as pharmacological (treatment with medication) and non-pharmacological (treatment with no medication). Laughter therapy has recently come to the fore as a non-pharmacological and alternative treatment in chronic pain management. In a randomized controlled study, 30 minutes of laughter therapy was applied to women on the 2nd and 6th days after mastectomy surgery and it was determined that women who received laughter therapy had a significant decrease in pain and anxiety levels. This study was planned to determine the effect of laughter therapy on women with migraine.

Clinical Trial Description

The research will be carried out with young girls who are studying at the Faculty of Health Sciences of Sinop University in the 2022-2023 academic spring semester. Inclusion criteria for the research: Faculty of Health Sciences, to study in the 2022-2023 academic spring semester, to have been diagnosed with migraine, to be young girls and to volunteer to participate in the research. Exclusion criteria from the study; Not studying at the Faculty of Health Sciences and not volunteering to participate in the research. The application and control group will be determined on random.org among the group that constitutes the sample of the study. Laughter therapy sessions will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. At the end of two months, the Personal Information Form and Psychological Well-Being Scale will be administered again to both the application group and the control group. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05804812
Study type	Interventional
Source	Sinop University
Contact
Status	Completed
Phase	N/A
Start date	April 6, 2023
Completion date	June 28, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06192173` - Patent Foramen Ovale Closure in Migraine
Completed	`NCT05525611` - Cabergoline as a Preventive Treatment for Chronic Migraine	N/A
Recruiting	`NCT03832998` - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine	Phase 3
Enrolling by invitation	`NCT04196933` - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma	N/A
Not yet recruiting	`NCT06428838` - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context	Phase 3
Completed	`NCT06304675` - Manageable Environmental Factors in Migraine
Completed	`NCT04084314` - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study	Phase 4
Recruiting	`NCT05517200` - Pilot Study for a Machine Learning Test for Migraine
Completed	`NCT04179474` - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine	Phase 1
Recruiting	`NCT04603976` - Registry for Migraine - Clinical Core	Phase 4
Completed	`NCT03597529` - CHOCOlate MeLatonin for AdolescenT MigrainE	Phase 2
Completed	`NCT04197349` - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman	Phase 1
Recruiting	`NCT05891808` - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting	`NCT05064371` - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan	Phase 3
Suspended	`NCT04069572` - Vibratory Stimulation for the Treatment of Chronic Pain	N/A
Not yet recruiting	`NCT04859374` - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach	N/A
Not yet recruiting	`NCT03083860` - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.	N/A
Completed	`NCT02905227` - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder	Phase 1
Enrolling by invitation	`NCT02532023` - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients	Phase 4
Completed	`NCT02108678` - One-Day Intervention for Depression and Impairment in Migraine Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.